The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Lifestyle: Wearing Makeup

Back to News Homepage

Next

Hep C Studies on Faldaprevir Will Be Heard at EASL

New Drug Application Submitted for Gilead’s Sofosbuvir

April 16, 2013

Print this page

Gilead has taken the next step for bringing an all-oral Hepatitis C treatment to fruition, submitting a new drug application to the FDA for their nucleotide analogue, sofosbuvir.

Gilead Submits NDA to FDA for Sofosbuvir for the Treatment of Hepatitis C

Tue, 04/09/2013

Gilead Sciences today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection. The data submitted in this NDA support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 HCV infection, and for sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection.

Chronic HCV infection affects up to four million Americans, particularly individuals born between 1946 and 1964. The disease is the leading cause of liver cancer and liver transplantation in the United States. Treatment for HCV currently includes 24-48 weeks of therapy with peg-IFN, which has to be injected and is associated with significant side effects, leaving some patients unable to complete therapy. If approved, sofosbuvir would shorten HCV therapy to 12 to 16 weeks, and depending on the genotype, would either eliminate or reduce the duration of peg-IFN injections.

Continue reading this entire article:
http://www.pharmpro.com/news/2013/04/gilead-submits-nda-fda-sofosbuvir-treatment-hepatitis-c

56 Comments
Share
Share

Previous

Hepatitis C Lifestyle: Wearing Makeup

Back to News Homepage

Next

Hep C Studies on Faldaprevir Will Be Heard at EASL

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.